Cargando…

Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial

BACKGROUND: Ilorasertib (ABT-348) inhibits Aurora and VEGF receptor (VEGFR) kinases. Patients with advanced solid tumours participated in a phase 1 dose-escalation trial to profile the safety, tolerability, and pharmacokinetics of ilorasertib. METHODS: Ilorasertib monotherapy was administered at 10–...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maitland, Michael L., Piha-Paul, Sarina, Falchook, Gerald, Kurzrock, Razelle, Nguyen, Ly, Janisch, Linda, Karovic, Sanja, McKee, Mark, Hoening, Elizabeth, Wong, Shekman, Munasinghe, Wijith, Palma, Joann, Donawho, Cherrie, Lian, Guinan K., Ansell, Peter, Ratain, Mark J., Hong, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5931107/ https://www.ncbi.nlm.nih.gov/pubmed/29551775 http://dx.doi.org/10.1038/s41416-018-0020-2

Ejemplares similares

Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus
por: Piha-Paul, Sarina A., et al.
Publicado: (2014)

Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study
por: Munasinghe, Wijith, et al.
Publicado: (2016)

P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy
por: Said, Rabih, et al.
Publicado: (2013)

Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population
por: Wheler, Jennifer, et al.
Publicado: (2013)

Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer
por: Falchook, Gerald S., et al.
Publicado: (2014)

Dual EGFR inhibition in combination with anti-VEGF treatment: A phase I clinical trial in non-small cell lung cancer
por: Falchook, Gerald S., et al.
Publicado: (2013)

ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition
por: Anderson, Mark G., et al.
Publicado: (2021)

Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials
por: Subbiah, Ishwaria M., et al.
Publicado: (2015)

Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine
por: Tsimberidou, Apostolia-Maria, et al.
Publicado: (2019)

Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial
por: Subbiah, Vivek, et al.
Publicado: (2020)

Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway
por: Wheler, Jennifer J., et al.
Publicado: (2014)

PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes
por: Janku, Filip, et al.
Publicado: (2012)

348. Etiology of Eosinophilic Meningitis in Korea
por: Park, Sunghee, et al.
Publicado: (2020)

Health Tract No. 348: Night Air
Publicado: (1868)

Targeted Therapy of Advanced Gallbladder Cancer and Cholangiocarcinoma with Aggressive Biology: Eliciting Early Response Signals from Phase 1 trials
por: Subbiah, Ishwaria M., et al.
Publicado: (2013)

Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy
por: Tsimberidou, Apostolia M, et al.
Publicado: (2015)

Multikinase Inhibitor Treatment in Thyroid Cancer
por: Ancker, Ole Vincent, et al.
Publicado: (2019)

Rare complications of multikinase inhibitor treatment
por: Pitoia, Fabián, et al.
Publicado: (2018)

Test Run Report of the P348 Collaboration
por: Gninenko, S N
Publicado: (2015)

Clinical Characteristics for 348 Patients with Adrenal Incidentaloma
por: Kim, Jongho, et al.
Publicado: (2013)

Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials
por: Said, Rabih, et al.
Publicado: (2014)

Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: The university of Texas MD Anderson cancer center experience
por: Corrales-Medina, Fernando F., et al.
Publicado: (2014)

348 Immunomodulatory Effects of Extracorporeal Photochemotherapy in Systemic Sclerosis
por: Zeher, Margit, et al.
Publicado: (2012)

P348 tRNA modifications in Candida virulence
por: Böttcher, Bettina, et al.
Publicado: (2022)

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
por: Kumar, R, et al.
Publicado: (2009)

Inositol polyphosphate multikinase signaling in the regulation of metabolism
por: Lee, Joo-Young, et al.
Publicado: (2012)

Multikinase inhibitors use in differentiated thyroid carcinoma
por: Jasim, Sina, et al.
Publicado: (2014)

Daily Management of Patients on Multikinase Inhibitors’ Treatment
por: Colombo, Carla, et al.
Publicado: (2022)

Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors
por: Naing, Aung, et al.
Publicado: (2013)

Platón (428-348 a. C.) en 90 minutos /
por: Strathern, Paul, 1940-
Publicado: (1998)

P348: Medical emergencies in national hospital of Lamorde, Niger
por: Djibo, H, et al.
Publicado: (2013)

THU348 Thyroid Dysfunction And Diabetes In Pregnancy - Is There A Link?
por: Kumar Sahay, Rakesh, et al.
Publicado: (2023)

Emerging role of multikinase inhibitors for refractory thyroid cancer
por: Perez, Cesar A, et al.
Publicado: (2012)

Exploring Selectivity of Multikinase Inhibitors across the Human Kinome
por: Miljković, Filip, et al.
Publicado: (2018)

Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib
por: Lin, Tong, et al.
Publicado: (2017)

Targeting RET-rearranged lung cancers with multikinase inhibitors
por: Sabari, Joshua K., et al.
Publicado: (2017)

Timing of multikinase inhibitor initiation in differentiated thyroid cancer
por: Brose, Marcia S, et al.
Publicado: (2017)

Gastrointestinal Tract Homeostasis: The Role of the Inositol Polyphosphate Multikinase
por: Saiardi, Adolfo
Publicado: (2022)

BRAF Mutations in Advanced Cancers: Clinical Characteristics and Outcomes
por: El-Osta, Hazem, et al.
Publicado: (2011)

MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit
por: Jardim, Denis L. Fontes, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_kshf8lfbqkp8gljl4rqolt5sk5